Progress in drug therapy for COVID-19 infection

The novel coronavirus pneumonia caused by COVID-19 has emerged in Wuhan at the end of Dec. 2019, and then has spread across our country. To date, no specific therapy against the new virus is available. The clinical efficacy of some antiviral drugs, such as remdesivir, chloroquine phosphate, abidor a...

Full description

Bibliographic Details
Published in:	Jichu yixue yu linchuang
Main Author:	LIU Fang-yuan, SU Xiu-lan
Format:	Article
Language:	Chinese
Published:	Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. 2020-10-01
Subjects:	novel coronavirus\|antiviral therapy\|antiviral peptide\|antibody
Online Access:	http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/a200424.pdf

Similar Items

Plant-Based Drugs and Vaccines for COVID-19
by: Nasir Mahmood, et al.
Published: (2020-12-01)

Current Perspective on the Treatment of the Novel Coronavirus Infection COVID-19
by: I. Kh. Borukaeva, et al.
Published: (2025-06-01)

Direct antiviral drugs and blocking monoclonal antibodies as the basis of etiotropic therapy of a novel coronavirus infection
by: V. B. Musatov
Published: (2022-10-01)

The application and prospects of antimicrobial peptides in antiviral therapy
by: Fei Yang, et al.
Published: (2024-12-01)

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
by: Evi B. Struble, et al.
Published: (2023-05-01)

Assessing Genomic Mutations in SARS-CoV-2: Potential Resistance to Antiviral Drugs in Viral Populations from Untreated COVID-19 Patients
by: Daniele Lombardo, et al.
Published: (2023-12-01)

COVID-19 therapy: from myths to reality and hopes
by: S. V. Bozrova, et al.
Published: (2020-12-01)

Prospects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infection
by: Oleg V. Maltsev, et al.
Published: (2022-11-01)

Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance
by: Salvatore Rotundo, et al.
Published: (2025-04-01)

CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease
by: Ilaria Mastrorosa, et al.
Published: (2025-08-01)

Pharmacokinetics of Molnupiravir in Cats with Naturally Occurring Feline Infectious Peritonitis
by: Petra Černá, et al.
Published: (2025-07-01)

Pharmacological Effects and Clinical Prospects of Cepharanthine
by: Di Liang, et al.
Published: (2022-12-01)

The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication
by: Stuart Weston, et al.
Published: (2025-10-01)

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
by: Emily L.C. Tan, et al.
Published: (2004-04-01)

Evaluation of the effect of favipiravir on patients with COVID-19
by: Alireza Kamali, et al.
Published: (2023-02-01)

Remdesivir as a potential antiviral agent for COVID-19: A literature review
by: Susanna Josey
Published: (2020-01-01)

Antimicrobial Peptides as Potential Antiviral Factors in Insect Antiviral Immune Response
by: Min Feng, et al.
Published: (2020-09-01)

Antiviral effect of the viroporin inhibitors against Taiwan isolates of infectious bronchitis virus (IBV)
by: Mikael Cristofer Sitinjak, et al.
Published: (2024-11-01)

Antivirals blocking entry of enteroviruses and therapeutic potential
by: Mohd Ishtiaq Anasir, et al.
Published: (2021-01-01)

THE LEVEL OF ANTIVIRAL ANTIBODIES AND INDEXES OF LOCAL IMMUNITY INTHE DYNAMICS OF THE TREATMENT OF CHILDREN WITH GLOMERULONEPHRITIS IN THE PRESENCE OF HERPESVIRAL INFECTION
by: V. Kruglikov, et al.
Published: (2016-08-01)

Cyanobacterial metabolites as novel drug candidates in corona viral therapies: A review
by: Srinivasan Prabhu, et al.
Published: (2022-09-01)

Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
by: Li L, et al.
Published: (2020-07-01)

Antivirals for Broader Coverage against Human Coronaviruses
by: Mia Outteridge, et al.
Published: (2024-01-01)

Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy
by: Sania Batool, et al.
Published: (2023-01-01)

The Synthetic Peptide GA-Hecate and Its Analogs Inhibit Multiple Steps of the Chikungunya Virus Infection Cycle In Vitro
by: Gabriela Miranda Ayusso, et al.
Published: (2023-09-01)

Coronavirus Disease 2019 Case Series in China: Sequelae and Effectiveness of Vaccination and Antiviral Drugs
by: Ren M
Published: (2025-02-01)

The Identification of Peptide Inhibitors of the Coronavirus 3CL Protease from a <i>Fucus ceranoides</i> L. Hydroalcoholic Extract Using a Ligand-Fishing Strategy
by: Luiz Antonio Miranda de Souza Duarte Filho, et al.
Published: (2024-05-01)

The Dimeric Peptide (KKYRYHLKPF)<sub>2</sub>K Shows Broad-Spectrum Antiviral Activity by Inhibiting Different Steps of Chikungunya and Zika Virus Infection
by: Gabriela Miranda Ayusso, et al.
Published: (2023-05-01)

Prediction of the mechanism of action of catechin as superoxide anion antioxidants and natural antivirals for COVID-19 infection with in silico study
by: Achmad Zainuddin, et al.
Published: (2022-01-01)

Editorial: Plant products for antiviral therapeutics
by: Anirban Mandal, et al.
Published: (2022-10-01)

Comparative evaluation of authorized drugs for treating Covid‐19 patients
by: Towhidul Islam, et al.
Published: (2022-07-01)

Evaluation of Hepatic Biochemical Parameters during Antiviral Treatment in COVID-19 Patients
by: Felicia Marc, et al.
Published: (2021-12-01)

Antiviral Drug Discovery for the Treatment of COVID-19 Infections
by: Teresa I. Ng, et al.
Published: (2022-05-01)

Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review
by: Anna Starshinova, et al.
Published: (2021-07-01)

Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study
by: Emma Cosaro, et al.
Published: (2023-08-01)

Surveillance and Stewardship Approaches for COVID-19 Novel Therapeutics in England from 2021 to 2022 (ESPAUR Report)
by: Alessandra Løchen, et al.
Published: (2023-03-01)

Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies
by: Paolo Bottino, et al.
Published: (2023-09-01)

PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity
by: Sijia He, et al.
Published: (2020-12-01)

The pan-variant potential of light: 425 nm light inactivates SARS-CoV-2 variants of concern and non-cytotoxic doses reduce viral titers in human airway epithelial cells
by: Nathan Stasko, et al.
Published: (2025-06-01)

Identification and Tracking of Antiviral Drug Combinations
by: Aleksandr Ianevski, et al.
Published: (2020-10-01)